Cancer Chemotherapy and Pharmacology

, Volume 36, Issue 5, pp 425–430

Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study

  • Ronald A. Fleming
  • Robert L. Capizzi
  • Gary L. Rosner
  • Lawrence K. Oliver
  • Stephen J. Smith
  • Charles A. Schiffer
  • Richard T. Silver
  • Bruce A. Peterson
  • Raymond B. Weiss
  • George A. Omura
  • Robert J. Mayer
  • David A. Van Echo
  • Clara D. Bloomfield
  • Richard L. Schilsky
Original Article Cytarabine, Leukemia

DOI: 10.1007/BF00686192

Cite this article as:
Fleming, R.A., Capizzi, R.L., Rosner, G.L. et al. Cancer Chemother. Pharmacol. (1995) 36: 425. doi:10.1007/BF00686192

Abstract

The pharmacokinetics of cytarabine (ara-C) were determined in 265 patients with acute myeloid leukemia (AML) receiving ara-C (200 mg/m2 per day for 7 days as a continuous infusion) and daunorubicin during induction therapy. The mean (standard deviation) ara-C concentration at steady-state (Css) and systemic clearance (Cl) were 0.30 (0.13) μM and 134 (71) l/h per m2 respectively. Males had a significantly faster ara-C Cl (139 vs 131 l/h per m2,P=0.025) than females. Significant correlations were noted between ara-C Cl and the pretreatment, peripheral white blood cell count (P=0.005) and pretreatment blast count (P=0.020). No significant differences in ara-C Css or Cl were noted in patients achieving complete remission compared with those failing therapy (P=0.315,P=0.344, respectively). No significant correlations were observed between ara-C pharmacokinetic parameters and several indices of patient toxicity. Our findings indicate that variability in ara-C disposition in plasma at this dosage level does not correlate with remission status or toxicity in patients with AML receiving initial induction therapy with ara-C and daunorubicin.

Key words

CytarabineLeukemia

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • Ronald A. Fleming
    • 1
  • Robert L. Capizzi
    • 1
  • Gary L. Rosner
    • 2
  • Lawrence K. Oliver
    • 3
  • Stephen J. Smith
    • 1
  • Charles A. Schiffer
    • 4
  • Richard T. Silver
    • 5
  • Bruce A. Peterson
    • 6
  • Raymond B. Weiss
    • 7
  • George A. Omura
    • 8
  • Robert J. Mayer
    • 9
  • David A. Van Echo
    • 4
  • Clara D. Bloomfield
    • 10
  • Richard L. Schilsky
    • 11
  1. 1.Medical Center BoulevardComprehensive Cancer Center of Wake Forest UniversityWinston-SalemUSA
  2. 2.Duke University Medical CenterDurhamUSA
  3. 3.The Upjohn CompanyKalamazooUSA
  4. 4.University of Maryland Cancer CenterBaltimoreUSA
  5. 5.The New York HospitalNew YorkUSA
  6. 6.University of Minnesota Medical SchoolMinneapolisUSA
  7. 7.Walter Reed Army Medical CenterWashington DCUSA
  8. 8.The University of Alabama at BirminghamBirminghamUSA
  9. 9.Dana-Farber Cancer InstituteBostonUSA
  10. 10.Roswell Park Cancer InstituteBuffaloUSA
  11. 11.Cancer Research CenterUniversity of ChicagoChicagoUSA
  12. 12.US BioscienceWest ConshohockenUSA